Altering the Prime Affects ALVAC-SIV/gp120 Immunogenicity and Efficacy
Background: The 31.2% efficacy afforded by ALVAC-HIV/gp120 in the RV144 Thai Trial needs to be improved. ALVAC-SIV/gp120 vaccines tested in a SIVmac251 macaque model also demonstrated partial efficacy ~40% at each challenge. DNA vaccines and alternate adenoviral vectors such as Adenovirus 26 are clinically relevant vaccine candidates that could be used in combination with ALVAC/gp120.…